BEIJING, Sept. 4, 2024 /PRNewswire/ — CASI Prescribed drugs (NASDAQ:), Inc. (Nasdaq: CASI) (“CASI” or the “Firm”), a Cayman integrated biopharmaceutical firm specializing within the improvement and commercialization of modern therapeutics and pharmaceutical merchandise, at this time introduced its participation within the H.C. Wainwright 26th Annual World Funding Convention happening September Sep 11, 2024, on the Lotte New York Palace in New York Metropolis. Members of the CASI administration group, together with Chief Monetary Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, will host 1×1 investor conferences on the convention.
A pre-recorded company presentation will probably be out there for convention individuals to view in “Digital Room 1” at 7 a.m. Jap Time on September ninth. Thereafter, the presentation will probably be out there on the Buyers web page of the CASI company web site at https://casipharmaceuticals.com/investor.html.
About CASI Prescribed drugs
CASI Prescribed drugs, Inc. is a biopharmaceutical firm targeted on growing and commercializing modern therapeutics and pharmaceutical merchandise in China, the USA, and all through the world. The Firm is concentrated on buying, growing, and commercializing merchandise that increase its concentrate on hematology oncology therapeutics and therapeutics for organ transplant rejection and autoimmune illness, in addition to different areas of unmet medical want. The Firm intends to execute its plan to change into a pacesetter by launching medicines within the Better China market, leveraging the Firm’s China-based regulatory and business competencies and its international drug improvement experience. The Firm’s operations in China are carried out via its wholly owned subsidiary, CASI Prescribed drugs (China) Co., Ltd., situated in Beijing, China. Extra data on CASI is out there at www.casipharmaceuticals.com.
COMPANY CONTACT:Rui ZhangCASI Prescribed drugs, Inc.
240.864.2643
ir@casipharmaceuticals.com
